Safety of Baricitinib in Japanese Patients with Rheumatoid Arthritis (RA): The 2020 Interim Report from All-case Post Marketing Surveillance in Clinical Practice

被引：0

作者：

Fujii, Takao ^{[1
]}

Atsumi, Tatsuya ^{[2
]}

Okamoto, Nami ^{[3
]}

Takahashi, Nobunori ^{[4
]}

Tamura, Naoto ^{[5
]}

Nakajima, Atsuo ^{[6
]}

Nakajima, Ayako ^{[7
]}

Matsuno, Hiroaki ^{[8
]}

Tsujimoto, Naoto ^{[9
]}

Nishikawa, Atsushi ^{[9
]}

Ishii, Taeko ^{[9
]}

Takeuchi, Tsutomu ^{[10
]}

Kuwana, Masataka ^{[11
]}

Takagi, Michiaki ^{[12
]}

机构：

[1] Wakayama Med Univ, Dept Rheumatol & Clin Immunol, Wakayama, Japan

[2] Hokkaido Univ, Sapporo, Hokkaido, Japan

[3] Osaka Med Coll, Takatsuki, Osaka, Japan

[4] Nagoya Univ, Grad Sch Med, Nagoya, Aichi, Japan

[5] Juntendo Univ, Fac Med, Dept Internal Med & Rheumatol, Tokyo, Japan

[6] Ueno Touseki Clin, Fukuoka, Japan

[7] Mie Univ Hosp, Ctr Rheumat Dis, Tsu, Mie, Japan

[8] Matsuno Clin Rheumat Dis, Toyama, Japan

[9] Eli Lilly Japan KK, Kobe, Hyogo, Japan

[10] Keio Univ, Div Rheumatol, Tokyo, Japan

[11] Nippon Med Sch, Grad Sch Med, Dept Allergy & Rheumatol, Tokyo, Japan

[12] Yamagata Univ, Fac Med, Dept Orthopaed Surg, Yamagata, Japan

来源：

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1676

引用

页码：3489 / 3490

页数：2